A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
- Conditions
- Primary Progressive Nonfluent Aphasia
- Interventions
- Drug: AADvac1 40 µgDrug: AADvac1 160 µg
- Registration Number
- NCT03174886
- Lead Sponsor
- Axon Neuroscience SE
- Brief Summary
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia.
50% of participants will receive the 40 µg dosage of AADvac1 and 50% of participants will receive the 160 µg dosage of AADvac1. No placebo is used.
- Detailed Description
The non-fluent variant of Primary progressive Aphasia (nfvPPA) is a chronic progressive neurodegenerative disorder of the brain. Over the course of the disease, pathological proteins accumulate in the brain, damaging neurons, thus causing them to lose their connections and die.
No treatments are currently available; symptomatic medications are used off-label in nfvPPA.
AADvac1 is designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology, which is the underlying cause of disease in \~80% of nfvPPA cases). These antibodies are expected to prevent tau protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the spreading of pathology, slowing or halting the progress of the disease.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 33
Not provided
-
The patient's brain MRI is incompatible with a diagnosis of nfvPPA.
-
Patient has a history or evidence of a central nervous system (CNS) disorder other than nfvPPA which may cause symptoms of aphasia or dementia (Alzheimer's disease, Dementia with Lewy Bodies, inflammatory/demyelinating CNS conditions, Creutzfeldt-Jakob disease, Huntington's disease, etc.)
-
Patient has a history or currently suffers from a significant psychiatric illness such as schizophrenia, any type of psychotic disorder or bipolar affective disorder.
-
Patient has a history or evidence of cerebrovascular disease (ischemic or haemorrhagic stroke), or diagnosis of possible, probable or definite vascular dementia.
-
Patient has Wernicke's encephalopathy.
-
Patient has metabolic or toxic encephalopathy or dementia due to a general medical condition.
-
Patient suffers from hypothyroidism, defined as thyroid-stimulating hormone elevation > 5.000 mcIU/mL, and/or fT4 levels < 0.7 ng/dL. Patients with corrected hypothyroidism are eligible for the study provided that treatment has been stable for 12 weeks before study entry.
-
Patient has a known pathogenic mutation in GRN or C9orf72.
-
Presence or history of allergy to components of the vaccine.
-
Presence and/or history of immunodeficiency (e.g., HIV).
-
Patient is currently being treated with immunosuppressive drugs.
-
Patient has a history and/or currently suffers from a clinically significant autoimmune disease, or is expected to receive immunosuppressive or immunomodulatory treatment at the present or in the future.
-
Patient has a recent (≤ 5 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia).
-
Patient has an active infectious disease (e.g., Hepatitis B, C).
-
Patient had a myocardial infarction within the last 2 years.
-
Patient has a current clinically important systemic illness that is likely to result in deterioration of the patient's condition or affect the subject's safety during the study:
- poorly controlled congestive heart failure (New York Heart Association [NYHA] score ≥ 3),
- poorly controlled diabetes,
- severe renal insufficiency (Estimated glomerular filtration rate < 30 mL/min),
- chronic liver disease - ALT (alanine aminotransferase) > 2x upper limit of normal range (ULN), AST (aspartate aminotransferase) > 2x ULN
- other clinically significant systemic illness, if considered relevant by the investigator.
-
Patient had alcohol or drug dependence within the past year.
-
Patient has a current diagnosis of epilepsy.
-
Pregnant or breastfeeding women.
-
Patient has participated in another interventional clinical trial within 12 weeks before Visit 01.
-
Patient has contraindication for MRI imaging such as metallic endoprosthesis or MRI-incompatible stent implantation.
-
Patient has contraindications for other study procedures, such as CSF sampling.
-
Patient had surgery (under general anaesthesia) within 12 weeks prior to Visit 01 and/or scheduled surgery (under general anaesthesia) during the whole study period.
-
Patient is currently being treated or was treated in the past with any active vaccines for a neurodegenerative disorder.
-
Patients not expected to complete the clinical trial.
-
Patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol, or is unsuitable for other reasons.
-
Patient is dependent from Sponsor or investigator (e.g. as an employee or as a relative).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description AADvac1 40 µg AADvac1 40 µg The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations. AADvac1 160 µg AADvac1 160 µg The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
- Primary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] 25 months The safety assessment is based on the number, type and severity of adverse events (AEs).
Immunogenicity (Percentage of patients who develop an IgG immune response, geometric mean titre of titre of antibodies against Axon Peptide 108, IgG to IgM ratio of antibodies against Axon Peptide 108) 24 months AADvac1 depends on raising antibodies that mediate its treatment effects. Immunogenicity assessment includes: Percentage of AADvac1-treated patients who develop an immune response (responder rate), geometric mean titre of antibodies against Axon Peptide 108, IgG to IgM ratio of antibodies against Axon Peptide 108.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Universitätsmedizin Göttingen, Klinik für Psychiatrie und Psychotherapie
🇩🇪Göttingen, Germany
Klinikum Rechts der Isar der TU München, Klinik und Poliklinik für Psychiatrie und Psychotherapie
🇩🇪München, Germany
Universitätsklinikum Ulm
🇩🇪Ulm, Germany